# **Topical Collection**

# Nanoparticles for Therapeutic and Diagnostic Applications

## Message from the Collection Editor

Nanoparticles have garnered intense interest as a therapeutic platform to treat a broad range of diseases, including cancer, metabolic, cardiovascular, skin, renal, inflammatory, and infectious disease. Well-designed nanoparticles can enhance the efficacy of traditional therapeutics through enhanced solubility, prolonged circulation or drug release, targeted delivery to disease sites, and reduced toxicity. Nanoparticles can be formulated for systemic, dermal, oral, and inhalation applications and optimized to overcome the delivery barriers of emerging therapeutics such as oligonucleotides, mRNA, and DNA with the potential to be safer than viral vector counterparts. The Issue will focus on nanoparticle development and applications in broad ranges of diseases and delivery routes. Research toward increased understanding of pharmacokinetics, pharmacodynamics, toxicity, stability, and manufacturability of nanoparticles is also highly relevant. We look forward to receiving your contributions to this Issue of Bioengineering.

#### Collection Editor

Prof. Dr. Wassana Yantasee

Department of Biomedical Engineering, Oregon Health and Science University, Portland, OR 97239, USA



# **Bioengineering**

an Open Access Journal by MDPI

Impact Factor 3.7
CiteScore 5.3
Indexed in PubMed



mdpi.com/si/14355

Bioengineering
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
bioengineering@mdpi.com

mdpi.com/journal/bioengineering





# **Bioengineering**

an Open Access Journal by MDPI

Impact Factor 3.7 CiteScore 5.3 Indexed in PubMed



# **About the Journal**

## Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Bioengineering* (ISSN 2306-5354). *Bioengineering* is published in open access format – research articles, reviews and other contents are released on the Internet immediately after acceptance. The scientific community and the general public have unlimited and free access to the content as soon as it is published. *Bioengineering* provides an advanced forum for the science and technology of bioengineering. We would be pleased to welcome you as one of our authors.

#### Editor-in-Chief

Prof. Dr. Anthony Guiseppi-Elie Department of Biomedical Engineering, Texas A&M University, College Station, TX 77843, USA

### **Author Benefits**

## **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, Inspec, and other databases.

#### Journal Rank:

JCR - Q2 (Engineering, Biomedical) Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.2 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

#### **Recognition of Reviewers:**

reviewers who provide timely, thorough peer-review reports receive vouchers entitling them to a discount on the APC of their next publication in any MDPI journal, in appreciation of the work done.

